Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients

International Journal of Radiation Oncology Biology Physics

Volumn 35, Issue 5, 1996, Pages 885-889

  Stattin, Pär ^b   Damber, Jan Erik ^b   Modig, Hans ^b   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b NONE

Author keywords

Immunohistochemistry; p53; Prognostic marker; Prostate cancer; Radiation; Survival; Transurethral resection

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RADIOSENSITIVITY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0030586040     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(96)00134-4     Document Type: Article

References (34)

1. 1. Allred, G. M.; Elledge, R.; Fuqua, S. A.; Brown, R. W.; Chamness, G. C.; Osborne, C. K.; McGuire, W. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. 85:200-206; 1993.
2. 2. Campbell, M. J.; Machin, D. Medical statistics. 2nd ed. Chichester: Wiley; 1993.
3. 3. Clarke, A. R.; Purdie, C. A.; Harrison, D. J.; Morris, C. C.; Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852; 1993.
4. 4. Fan, S.; El-Deiry, W. S.; Bae, L; Freeman, J.; Jondle, D.; Bhatia, K.; Fornace, A. J.; Magrath, I. M.; Kohn, K. W.; O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54:5824-5830; 1994.
5. 5. Greenblatt, M. S.; Bennett, W. P.; Hollstein, M.; Harris, C. C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878; 1994.
6. 6. Grignon, D.; Caplan, R.; Sarkar, F.; Forman, J.; Mesic, J.; Fu, K.; Abrams, R.; Lawton, C. p53 suppressor gene mutations predict for failure following combined neoadjuvant total androgen ablation and external beam therapy for locally advanced prostate cancer: A study based on RTOG protocol 8610. J. Urol. 153(Suppl. April):293A; 1995.
7. 7. Hall, P. A.; Lane, D. P. p53 in tumour pathology: Can we trust immunochemistry? - Revisited! J. Pathol. 172:1-4; 1994.
8. 8. Harris, C. C.; Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329:1318-1327; 1993.
9. 9. Hartwell, L. H.; Kastan, M. B. Cell cycle control and Cancer. Science 266:1821-1828; 1994.
10. 10. Jung, M.; Notario, V.; Dritschilo, A. Mutations in the p53 gene radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res. 52:6390-6393; 1992.
11. 11. Kabalin, J. N.; Hodge, K. K.; McNeal, J. E.; Freiha, F. S.; Stamey, T. A. Identification of residual cancer in the prostate following radiation therapy: Role of transrectal ultrasound guided biopsy and prostate specific antigen. J. Urol. 142:326-331; 1989.
12. 12. Kaplan, I. D.; Prestidge, B. R.; Bagshaw, M. A.; Cox, R. S. The importance of local control in the treatment of prostatic cancer. J. Urol. 147:917-921; 1992.
13. 13. Kemp, C. J.; Wheldon, T.; Balmain, A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet. 8:66-69; 1994.
14. 14. Kuerbitz, S. J.; Plunkett, B. S.; Walsh, W. V.; Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495; 1992.
15. 15. Levine, A. J.; Momand, J.; Finlay, C. A. The p53 tumour suppressor gene. Nature 351:435-456; 1991.
16. 16. Lowe, S. W.; Bodis, S.; McClatchey, A.; Remington, L.; Ruley, H. E.; Fisher, D. E.; Housman, D. E.; Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810; 1994.
17. 17. Lowe, S. W.; Ruley, H. E.; Jacks, T.; Housman, D. E. p53 dependent apoptosis modulates the cytotoxity of anticancer agents. Cell 74:957-967; 1993.
18. 18. Lowe, S. W.; Schmitt, E. M.; Smith, S. W.; Osborne, B. A.; Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849; 1993.
19. 19. MacGeoch, C.; Barnes, D. M.; Newton, J. A.; Mohammed, S.; Hodgson, S. V.; Ng, M.; Bishop, D. T.; Spurr, N. K. p53 protein detected by immunohistochemical staining is not always mutant. Dis. Markers 11:239-250; 1993.
20. 20. Merritt, A. J.; Potten, C. S.; Kemp, C. J.; Hickman, J. A.; Balmain, A.; Lane, D. P.; Hall, P. A. The role of p53 in spontaneous and radiation-induced apoptosisi in the gastrointestinal tract of normal and p53 deficient mice. Cancer Res. 54:614-617; 1994.
21. 21. Mostofi, F. K.; Sesterhenn, I. A.; Sobin, L. H. International histological classification of prostate tumours. Geneva: WHO; 1980.
22. 22. Navone, N. M.; Troncoso, P.; Pisters, L. L.; Goodrow, T. L.; Palmer, J. L.; Nichols, W. W.; von Eschenbach, A. C.; Conti, C. J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85:1657-1669; 1993.
23. 23. Norusis, M. J. SPSS for windows base system user's guide, professional statistics, advanced statistics release 6.0. Chicago: SPSS Inc.; 1993.
24. 24. Prendergast, N. J.; Atkins, M. R.; Schatte, E. C.; Paulson, D. F.; Walther, P. J. p53 genetic alterations are associated at high incidence with postirradiated locally persisent prostatic adenocarcinoma. A new radioresistance marker? J. Urol. 153(Suppl April):500A; 1995.
25. 25. Quinlan, D. C.; Davidson, A. G.; Summers, C. L.; Warden, H. E.; Doshi, H. Accumulation of p53 protein correlates with poor prognosis in human lung cancer. Cancer Res. 52:4828-4831; 1992.
26. 26. Shi, S. R.; Key, M. E.; Kalra, K. L. Antigen retrieval in formalin-fixed, paraffin embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem. 39:741-748; 1991.
27. 27. Slichenmeyer, W. J.; Nelson, W. G.; Slebos, R. J.; Kastan, M. B. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53:4164-4168; 1993.
28. 28. Stamey, T. A.; Kabalin, J. N.; Ferrari, M. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J. Urol. 141:1084-1087; 1989.
29. 29. Stattin, P.; Bergh, A.; Damber, J. E.; Karlberg, L. Accumulation of p53 protein identifies a subgroup of advanced prostate cancers with poor prognosis but p53 does not affect the prognosis after radiation. J. Urol. 153(Suppl. April):293A; 1995.
30. 30. Szumiel, I. Ionizing radiation-induced cell death. Int. J. Radiat. Biol. Biol. Phys. 66:329-341; 1994.
31. 31. UICC Union Internationale Contre le Cancer. TNM classification of malignant tumours. 2nd ed. Berlin: Springer; 1978.
32. 32. Visakorpi, T.; Kallioniemi, O. P.; Heikkinen, A.; Koivula, T.; Isola, J. Small subgroup of aggressive highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst. 84:883-887; 1992.
33. 33. Vojtesek, B.; Bartek, J.; Midgley, C. A.; Lane, D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. J. Immunol. Methods 151:237-244; 1992.
34. 34. Xia, F.; Wang, X.; Wang, Y. H.; Tsang, N. M.; Yandell, D. W.; Kelsey, K. T.; Liber, H. L. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res. 55:12-15; 1995.